Table 1.
Demographic and clinical characteristics of TOHVHP HCV group and the general population
| Variable | TOHVHP HCV group | General population | p-value |
|---|---|---|---|
| N = 1209 | N = 6045 | ||
| N(%) | N(%) | ||
| Age (yrs) (mean, SD) | 54.54 ± 11.42 | 54.54 ± 11.41 | 1.00 |
| Age (yrs) (median, IQR) | 56 (49–62) | 56 (49–62) | 1.00 |
| Age category | |||
| 16–25 | 15 (1.2%) | 75 (1.2%) | 1.00 |
| 26–35 | 77 (6.4%) | 385 (6.4%) | |
| 36–45 | 127 (10.5%) | 635 (10.5%) | |
| 46–55 | 369 (30.5%) | 1845 (30.5%) | |
| 56–65 | 464 (38.4%) | 2320 (38.4%) | |
| 66–75 | 122 (10.1%) | 610 (10.1%) | |
| 75+ | 35 (2.9%) | 175 (2.9%) | |
| Sex | 1.00 | ||
| Male | 782 (64.7%) | 3910 (64.7%) | |
| Female | 427 (35.3%) | 2135 (35.3%) | |
| Immigration status | 0.49 | ||
| Canadian citizen | 1056 (87.3%) | 5290 (87.5%) | |
| Immigrant from HCV endemic country | 54 (4.5%) | 230 (3.8%) | |
| Immigrant from non-endemic country | 99 (8.2%) | 525 (8.7%) | |
| HCV mono-infection | 1151 (95.2%) | – | |
| HCV-HIV co-infection | 53 (4.4%) | – | |
| HCV-HBV co-infection | 6 (0.5%) | – | |
| Time from HCV diagnosis | |||
| < 5 years from index date | 124 (10.3%) | – | |
| 5 to < 10 years from index date | 123 (10.2%) | – | |
| 10+ years from index date | 263 (21.8%) | – | |
| Missing | 699 (57.8%) | – | |
| Treatment statusa | |||
| Treated and cured | 690 (57.1%) | – | |
| Treated and not cured | 51 (4.2%) | – | |
| Never treated | 329 (27.2%) | – | |
| Missing | 139 (11.4%) | ||
| HCV treatment type (n = 741) | |||
| Direct acting antiviral (DAA) | 563 (76.0%) | – | |
| Interferon (IFN) | 178 (24.0%) | – | |
| Highest fibrosis score | |||
| 1 | 332 (27.5%) | – | |
| 2 | 171 (14.1%) | – | |
| 3 | 120 (9.9%) | – | |
| 4 | 309 (25.6%) | – | |
| Missing | 277 (22.9%) | – | |
| Prevalence of multimorbidity (at least two physical conditions) | 361 (29.9%) | 1259 (20.8%) | < 0.001 |
| Prevalence of physical-mental health multimorbidity | 299 (24.7%) | 574 (9.5%) | < 0.001 |
a 139 (11.5%) individuals could not be classified into any of the treatment status categories. Of these 33 (2.7%) were treated but had not completed their post-treatment bloodwork and cured status could not be determine, 72 (6.0%) were potentially LTFU, and 34 (2.8%) were unaccounted for (not found in either treatment database, but no record of lab test results (VL bloodwork))